Full Text View
Tabular View
No Study Results Posted
Related Studies
Phase III Study of 0.1% Tacrolimus(FK506) Ophthalmic Suspension in Patients With Vernal Keratoconjunctivitis
This study has been completed.
Study NCT00567762   Information provided by Astellas Pharma Inc
First Received: December 3, 2007   Last Updated: February 25, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Keratoconjunctivitis
Conjunctivitis
Additional conditions recognized in this trial
Conjunctivitis, Allergic
More general conditions related to this trial
Conjunctival Diseases
Corneal Diseases
Eye Diseases
Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases
Keratitis
Interventions listed in this trial
FK506
placebo
Additional drug interventions recognized in this trial
Tacrolimus
More general drug interventions related to this trial
Immunologic Factors
Immunosuppressive Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sponsors listed in this trial
Astellas Pharma Inc


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services